Restricted accessLetterFirst published online 2026-5
Letter: Beyond the Metrics: Translating Time in Range Gains into Global Health Equity. The Economic Case for Universal and Early Access to Diabetes Technology
HussainS, Ozdemir SaltikAZ, YuJJ, et al.Improving time-in-range in type 1 diabetes: Projecting the clinical and cost implications of automated insulin delivery. Diabetes Technol Ther, 2026; 28(3):206–218; doi: 10.1177/15209156251380593
2.
SantovaA, de BockM, LanzingerS, et al.; SWEET Study Group. Global inequities in diabetes technology and insulin access and glycemic outcomes. JAMA Netw Open, 2025; 8(8):e2528933.
3.
CherubiniV, ZucchiniS, BonfantiR, et al.Which treatment modalities are being used by Italian children and adolescents with type 1 diabetes? Diabetes Technol Ther, 2024; 26(4):283–285; doi: 10.1089/dia.2023.0510
4.
ConwayRB, Snell-BergeonJ, Honda-KohmoK, et al.Disparities in diabetes technology uptake in youth and young adults with type 1 diabetes: A global perspective. J Endocr Soc, 2024; 9(1):bvae210; doi: 10.1210/jendso/bvae210
5.
FangM, XuY, BallewSH, et al.Trends and disparities in technology use and glycemic control in type 1 diabetes. JAMA Netw Open, 2025; 8(8):e2526353; doi: 10.1001/jamanetworkopen.2025.26353
6.
MoesRGJ, HuismanEL, MalkinSJP, et al.Evaluating the clinical and economic outcomes associated with poor glycemic control in people with type 1 diabetes in the Netherlands. Clinicoecon Outcomes Res, 2023; 15:87–96; doi: 10.2147/CEOR.S391626
7.
JacobsonAM, BraffettBH, ClearyPA, et al.; DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: A 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care, 2013; 36(10):3131–3138; doi: 10.2337/dc12-2109
8.
MillerRG, OrchardTJ. Understanding metabolic memory: A tale of two studies. Diabetes, 2020; 69(3):291–299; doi: 10.2337/db19-0514
9.
RabboneI, SavastioS, CastoraniV, et al.The importance of instigating automated insulin delivery systems at onset of type 1 diabetes: 1-year follow-up of children and adolescents from two tertiary pediatric diabetes centers. Diabetes Technol Ther, 2025; 27(8):659–662; doi: 10.1089/dia.2025.0057
